Zealand Pharma is betting on new obesity and liver-disease medicines, but the race is moving fast and rivals may launch stronger or easier options first. Rising trial costs and lower patient stickiness could make it harder for the company’s pipeline and big pharma partnerships to deliver the growth many expect.Read more
Zealand Pharma has several major obesity drug trial readouts coming up, and its Roche partnership could help it reach patients worldwide if the results impress. But the story hinges on partners, tough competition, and whether the pipeline can prove it stands out without running into pricing and access pushback.Read more
Zealand Pharma teams up with Roche to push next‑generation peptide medicines for obesity and related conditions, with the promise of treatments people can stay on long term. The big question is whether its late‑stage studies and partner deals deliver before tougher competition and pricing rules squeeze the opportunity.Read more
No trending discussion available.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
